Literature DB >> 29550314

High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial.

James L Januzzi1, Sunil Suchindran2, Adrian Coles3, Maros Ferencik4, Manesh R Patel3, Udo Hoffmann5, Geoffrey S Ginsburg6, Pamela S Douglas7.   

Abstract

OBJECTIVES: The goal of this study was to examine associations between concentrations of high-sensitivity troponin I (hsTnI) (measured by using a single-molecule counting method) and obstructive coronary artery disease (CAD) in 1,844 stable, symptomatic outpatients with suspected CAD randomized to undergo coronary computed tomography angiography (CTA) in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial.
BACKGROUND: Elevated concentrations of hsTnI are associated with CAD in patients with myocardial infarction. The meaning of hsTnI concentrations in stable symptomatic outpatients is not well understood.
METHODS: Clinical characteristics and CTA results (including coronary artery calcium [CAC] scores) were expressed across hsTnI quartiles. Determinants of hsTnI concentration were identified. Multivariable logistic regression identified independent predictors of obstructive CAD50 (≥50% stenosis in any vessel) and CAD70 (≥70% stenosis or ≥50% left main).
RESULTS: The median hsTnI concentration was 1.5 ng/l; nearly all (98.5%) subjects had measurable hsTnI, and 6.1% had concentrations ≥99th percentile concentration for this assay (6 ng/l). Higher CAC scores, as well as more prevalent and diffuse CAD, was seen in upper hsTnI quartiles (all p < 0.001). Independent predictors of hsTnI concentrations included age, sex, and CAC score (all p < 0.05). After adjusting for demographic and clinical characteristics, log-transformed hsTnI concentrations were associated with obstructive CAD50 (odds ratio: 1.15 per interquartile range; p = 0.02) and CAD70 (odds ratio: 1.25 per interquartile range; p = 0.001).
CONCLUSIONS: In stable symptomatic outpatients undergoing nonemergent coronary CTA for the diagnosis of suspected CAD, higher concentrations of hsTnI were associated with increasing presence and severity of coronary atherosclerosis. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery disease; coronary computed tomography angiography; troponin

Mesh:

Substances:

Year:  2018        PMID: 29550314      PMCID: PMC6129434          DOI: 10.1016/j.jcmg.2018.01.021

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  15 in total

Review 1.  Coronary Artery Calcium Score: the "Mammogram" of the Heart?

Authors:  Miguel Cainzos-Achirica; Philip A Di Carlo; Catherine E Handy; Renato Quispe; Gerard Roura; Xavier Pinto; Roger S Blumenthal; Josep Comin-Colet; Xavier Corbella; Michael J Blaha
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

Review 2.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

3.  Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.

Authors:  Maros Ferencik; Thomas Mayrhofer; Michael T Lu; Daniel O Bittner; Hamed Emami; Stefan B Puchner; Nandini M Meyersohn; Alexander V Ivanov; Elizabeth C Adami; Deepak Voora; Geoffrey S Ginsburg; James L Januzzi; Pamela S Douglas; Udo Hoffmann
Journal:  JACC Cardiovasc Imaging       Date:  2022-05-11

4.  Relationships Between Arterial Pressure-Volume Index and Cardiovascular Disease Biomarkers in Patients With Hypertension.

Authors:  Takashi Hitsumoto
Journal:  J Clin Med Res       Date:  2022-06-27

5.  Staged testing as a solution to the challenges of testing lower risk patients.

Authors:  Venkatesh L Murthy; Khurram Nasir
Journal:  J Nucl Cardiol       Date:  2018-09-17       Impact factor: 5.952

6.  Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium.

Authors:  Yader Sandoval; Suzette J Bielinski; Lori B Daniels; Michael J Blaha; Erin D Michos; Andrew P DeFilippis; Moyses Szklo; Christopher deFilippi; Nicholas B Larson; Paul A Decker; Allan S Jaffe
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

7.  Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque.

Authors:  Alastair J Moss; Marc R Dweck; Mhairi K Doris; Jack P M Andrews; Rong Bing; Rachael O Forsythe; Timothy R Cartlidge; Tania A Pawade; Marwa Daghem; Jennifer B Raftis; Michelle C Williams; Edwin J R van Beek; Laura Forsyth; Steff C Lewis; Robert J Lee; Anoop S V Shah; Nicholas L Mills; David E Newby; Philip D Adamson
Journal:  JACC Cardiovasc Imaging       Date:  2019-08-14

8.  Prognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin.

Authors:  Jo-Jo Hai; Yuen-Kwun Wong; Chun-Ka Wong; Ka-Chun Un; Pak-Hei Chan; Chung-Wah Siu; Kai-Hang Yiu; Chu-Pak Lau; Hung-Fat Tse
Journal:  BMC Cardiovasc Disord       Date:  2019-07-15       Impact factor: 2.298

9.  Impact of concurrent right ventricular myocardial infarction on outcomes among patients with left ventricular myocardial infarction.

Authors:  Huocheng Liao; Qiuyue Chen; Lin Liu; Sigan Zhong; Huazhao Deng; Chun Xiao
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

10.  Derivation and External Validation of a High-Sensitivity Cardiac Troponin-Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease.

Authors:  Cian P McCarthy; Johannes T Neumann; Sam A Michelhaugh; Nasrien E Ibrahim; Hanna K Gaggin; Nils A Sörensen; Sarina Schäefer; Tanja Zeller; Craig A Magaret; Grady Barnes; Rhonda F Rhyne; Dirk Westermann; James L Januzzi
Journal:  J Am Heart Assoc       Date:  2020-08-06       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.